The partnership connects the scrub brand to a leading national distributor LOS ANGELES & BOLINGBROOK, Ill.–(BUSINESS WIRE)–Premium scrubwear brand Jaanuu continues to broaden its reach, establishing a new partnership with S&S Activewear (S&S), a leading technology-enabled distributor of apparel and accessories in the United States and Canada. S&S operates eight nationwide distribution centers and has … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Cancer Immunotherapy – A Global Market Overview” report has been added to ResearchAndMarkets.com’s offering. The global market for Cancer Immunotherapy is estimated at US$135.2 billion in 2024 and is anticipated to post a CAGR of 9.8% during the 2024-2030 analysis period and stand at a projected US$236.9 billion by 2030. The global cancer … [Read more…]
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of … [Read more…]
PARIS–(BUSINESS WIRE)–Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of experienced biotechnology industry executive, Christophe Quéva, Ph.D., as Chief Executive Officer (CEO). With over 20 years of experience in the biotechnology industry, Dr. Quéva brings a wealth of … [Read more…]
Strong investor syndicate backs clinical-stage Hepatitis B program while advancing pioneering gene-tuning platform DURHAM, N.C. & SEATTLE–(BUSINESS WIRE)–Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation. “It is deeply gratifying to have seen this platform and company … [Read more…]
BIRMINGHAM, Ala.–(BUSINESS WIRE)–Medical Properties Trust, Inc. (the “Company” or “MPT”) (NYSE: MPW) today issued the below statement in response to Prospect Medical Group’s (“Prospect”) decision to commence an in-court restructuring process under Chapter 11 of the U.S. Bankruptcy Code. As discussed during MPT’s third quarter 2024 earnings, while Prospect’s California facilities have reported volume growth … [Read more…]
Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS Return of up to $300 million – maximum approved by shareholders – set to be completed in late January 2025 Builds on approximately $300 million returned to shareholders in … [Read more…]
This transaction accelerates scale-up of N-Power’s unique “always-on” prospective clinical research model, adding an extensive network of community health systems and 1,000+ community oncologists across the U.S. REDWOOD CITY, Calif.–(BUSINESS WIRE)–N-Power Medicine, a company leading the reinvention of the clinical trial process, today announced the acquisition of Syapse Holdings Inc. (“Syapse”), a pioneer in precision … [Read more…]
Commences Chapter 11 Proceedings to Effectuate Expedited Sales of Rhode Island Hospitals Company Continues to Work with the Commonwealth of Pennsylvania to Agree to Terms for Sale of the Crozer-Chester Medical Center Company is Engaging with Key Stakeholders to Finalize Necessary Funding to Support Business During Restructuring Process Company is Operating Uninterrupted Across All Regions … [Read more…]
— Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders — — Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S. — — LEO Pharma to Maintain … [Read more…]
